In the April issue of MedNousDr Steffen Thirstrup shares some thoughts around big data and its essential use in the post-authorisation period of a pharmaceutical.

Digital technology is changing how we collect data for research purposes, and the amount of information collected is growing exponentially. As drug development is focusing on more complex products targeting smaller populations, larger databases to establish the link between the drug and potential unwanted, and in certain cases, extremely rare events are required.

In this article, Dr Steffen Thirstrup explores the past and present approaches to coordinate the collection and analysis of real world data and present updates on the new EU Data Analysis and Real World Interrogation Network (DARWIN EU).

Author

Dr Steffen Thirstrup

LET’S TALK

You don't have to go it alone!

Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs

This field is for validation purposes and should be left unchanged.